Want to learn more about the OrthoLazer franchise opportunity? Watch our latest video to learn how we provide you with a GPS guided road map to success with an onboarding process unparalleled in the industry.
By partnering with OrthoLazer you can provide a much needed service to your community by offering an opioid alternative to acute and chronic pain.
In the post pandemic world, patients are seeking alternative options for pain relief.
Come join our team. Make a difference in your community.
The Centers for Disease Control (CDC) is updating its guidelines for opioid use (last updated in 2016). We are thrilled to report the proposed guidelines mention the benefit of low-level laser therapy (LLLT) as a potential non-pharmacologic treatment option for multiple pain scenarios.
Laser energy produces changes in oxidation/reduction status of the mitochondria which lead to dramatic increases in ATP synthesis. Activation of the sodium/potassium pump alters the cell membrane permeability to calcium. Laser therapy has been shown to effect cellular activity in the following ways: stimulate cell growth, increase cell metabolism, improve cell regeneration, produce an anti-inflammatory response, produce an edema reduction, reduce fibrous tissue formation, stimulate nerve function, reduce the production of Substance P, and stimulate long-term production of nitric oxide.
The MLS M8 Robotic Therapy Laser is free from any known side effects and has few contraindications. It is, therefore, safe to use for the majority of patients suffering from acute and chronic orthopedic conditions, as well as patients seeking to recover from surgery more quickly. Acute patients typically require 6 treatments over 2-3 weeks. Chronic patients are usually treated 8-12 times over 3-4 weeks. Treatment times range from 4-10 minutes, depending on the condition being treated.